Recently, the U.S. Food and Drug Administration (FDA) announced that an intravenous drug for treating multiple myeloma in people who have previously tried at least two other drugs was finally approved.
Multiple myeloma is a type of blood cancer that affects the plasma cells in bone marrow. Although the disease is relatively rare, when it persists, it is often deadly. In fact, according to the American Cancer Society, for this current year, nearly 21,700 new cases will be diagnosed and approximately 10,710 people will die from the disease in the U.S.
Furthermore, multiple myeloma can lead to more serious conditions like anemia, fractures, spinal cord compression, bone mass erosion, kidney failure, and other infectious diseases.
The approval of the new drug called “Kyprolis” is a product of Onyx Pharmaceutical Inc. Experts assumed that it might be the answer to those patients who have tried at least two drugs for their condition. Kyprolis was duly approved through an accelerated public application process but will still require further research. Nevertheless, previous clinical tests proved enough to allow the distribution of the drug to patients.
Experts further expected that the new drug will generate more sales to its manufacturer since its competing experimental drug from Bristol-Myers Squibb. Co. failed during a late stage trial. Moreover, the company expects the drug to be a great help for blood cancer patients since it definitely knows the dilemma that the patients go through.
Meanwhile, it is understandable that those who survived cancers and are often left with both physical and financial complications truly need help to qualify for social security disability benefit. Consequently, a Los Angeles permanent disability lawyer is willing to extend assistance for those cancer patients to somehow ease their emotional pain.
